See more : Bokusgruppen AB (publ) (BOKUS.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Guizhou Xinbang Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Nichirei Corporation (2871.T) Income Statement Analysis – Financial Results
- Brookfield Property Partners L.P. (BPYPO) Income Statement Analysis – Financial Results
- Lombard & Medot SA (MLCAC.PA) Income Statement Analysis – Financial Results
- Agra Ventures Ltd. (AGFAF) Income Statement Analysis – Financial Results
- BIQI International Holding Corporation (BIQIF) Income Statement Analysis – Financial Results
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.xinbang.com
About Guizhou Xinbang Pharmaceutical Co., Ltd.
Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.46B | 6.35B | 6.47B | 5.85B | 6.66B | 6.58B | 6.00B | 5.16B | 4.18B | 2.48B | 569.49M | 447.57M | 361.86M | 318.63M | 336.69M | 274.74M | 217.75M | 173.33M |
| Cost of Revenue | 5.23B | 5.13B | 5.12B | 4.59B | 5.19B | 5.15B | 4.75B | 4.05B | 3.32B | 1.84B | 213.94M | 166.98M | 128.71M | 111.23M | 103.40M | 85.39M | 76.64M | 60.74M |
| Gross Profit | 1.23B | 1.22B | 1.35B | 1.25B | 1.46B | 1.43B | 1.26B | 1.11B | 861.13M | 638.33M | 355.55M | 280.59M | 233.16M | 207.40M | 233.28M | 189.36M | 141.12M | 112.59M |
| Gross Profit Ratio | 19.02% | 19.16% | 20.90% | 21.42% | 22.01% | 21.79% | 20.93% | 21.49% | 20.60% | 25.78% | 62.43% | 62.69% | 64.43% | 65.09% | 69.29% | 68.92% | 64.81% | 64.96% |
| Research & Development | 4.67M | 1.21M | 1.94M | 10.56M | 36.58M | 36.69M | 30.17M | 25.39M | 6.94M | 5.01M | 7.30M | 6.03M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 118.55M | 149.92M | 127.19M | 124.15M | 149.48M | 156.71M | 103.89M | 83.54M | 77.29M | 36.76M | 32.42M | 20.44M | 16.13M | 34.61M | 27.02M | 23.91M | 15.53M | 14.16M |
| Selling & Marketing | 275.61M | 393.37M | 360.19M | 399.10M | 432.25M | 424.24M | 366.86M | 384.15M | 307.81M | 272.04M | 248.51M | 194.27M | 156.78M | 130.51M | 140.23M | 120.85M | 85.87M | 69.74M |
| SG&A | 394.16M | 543.29M | 487.38M | 523.25M | 581.73M | 580.95M | 470.75M | 467.69M | 385.09M | 308.80M | 280.94M | 214.71M | 172.91M | 165.12M | 167.26M | 144.75M | 101.40M | 83.90M |
| Other Expenses | 444.71M | 291.96M | 297.83M | 268.31M | 325.42M | -16.05M | -3.28M | 84.54M | 44.06M | 24.21M | 10.29M | 11.55M | -3.42M | 4.22M | 934.78K | 5.69M | 6.26M | 316.46K |
| Operating Expenses | 843.54M | 836.45M | 787.15M | 802.12M | 943.73M | 929.11M | 730.39M | 712.22M | 555.44M | 397.46M | 307.76M | 232.44M | 190.47M | 168.96M | 170.94M | 147.56M | 103.64M | 85.76M |
| Cost & Expenses | 6.08B | 5.97B | 5.91B | 5.40B | 6.13B | 6.08B | 5.48B | 4.76B | 3.87B | 2.24B | 521.70M | 399.42M | 319.17M | 280.19M | 274.35M | 232.94M | 180.27M | 146.49M |
| Interest Income | 12.73M | 13.54M | 14.00M | 15.37M | 17.12M | 16.27M | 24.08M | 28.96M | 16.28M | 10.13M | 6.15M | 11.14M | 15.92M | 4.56M | 266.33K | 369.42K | -0.07 | -0.32 |
| Interest Expense | 40.48M | 51.79M | 100.19M | 99.61M | 164.77M | 149.85M | 105.75M | 129.56M | 125.16M | 74.10M | 16.58M | 11.78M | 7.45M | 3.47M | 6.46M | 9.50M | 9.20M | 4.27M |
| Depreciation & Amortization | 255.83M | 269.54M | 275.59M | 264.62M | 274.62M | 233.08M | 181.10M | 156.70M | 126.66M | 50.10M | 19.74M | 7.55M | 6.80M | 7.42M | 7.61M | 7.58M | 6.92M | 7.20M |
| EBITDA | 672.43M | 608.73M | 768.65M | 632.49M | 734.63M | -825.85M | 699.48M | 471.42M | 480.01M | 323.24M | 84.32M | 76.70M | 66.15M | 55.04M | 61.80M | 48.74M | 44.52M | 28.35M |
| EBITDA Ratio | 10.41% | 10.57% | 12.35% | 11.32% | 11.49% | 11.11% | 11.91% | 12.99% | 11.83% | 13.32% | 14.96% | 17.70% | 19.41% | 17.44% | 21.28% | 20.16% | 20.45% | 16.36% |
| Operating Income | 385.03M | 427.82M | 451.51M | 429.91M | 526.57M | -1.20B | 422.42M | 231.18M | 184.41M | 175.05M | 37.49M | 45.87M | 48.60M | 38.92M | 53.25M | 32.92M | 28.07M | 21.16M |
| Operating Income Ratio | 5.96% | 6.74% | 6.98% | 7.35% | 7.91% | -18.17% | 7.04% | 4.48% | 4.41% | 7.07% | 6.58% | 10.25% | 13.43% | 12.21% | 15.82% | 11.98% | 12.89% | 12.21% |
| Total Other Income/Expenses | 10.99M | -2.93M | -30.39M | -162.45M | -195.09M | -16.05M | -3.28M | 84.54M | 43.79M | 23.98M | 10.29M | 11.49M | 4.93M | 5.23M | -5.26M | -3.38M | -2.75M | 298.62K |
| Income Before Tax | 396.02M | 313.39M | 421.12M | 267.46M | 331.48M | -1.21B | 419.13M | 312.01M | 228.20M | 199.04M | 47.78M | 57.36M | 53.53M | 44.14M | 54.19M | 38.58M | 34.41M | 21.45M |
| Income Before Tax Ratio | 6.13% | 4.94% | 6.51% | 4.58% | 4.98% | -18.41% | 6.98% | 6.05% | 5.46% | 8.04% | 8.39% | 12.82% | 14.79% | 13.85% | 16.09% | 14.04% | 15.80% | 12.38% |
| Income Tax Expense | 42.25M | 44.98M | 47.17M | 46.88M | 67.76M | 71.78M | 87.65M | 69.31M | 59.79M | 45.18M | 8.11M | 9.80M | 7.65M | 6.56M | 7.77M | 4.97M | 4.50M | 4.64M |
| Net Income | 287.23M | 224.37M | 373.96M | 173.52M | 236.30M | -1.30B | 319.38M | 246.01M | 174.38M | 144.77M | 40.24M | 47.83M | 46.08M | 37.76M | 46.42M | 33.61M | 29.91M | 17.45M |
| Net Income Ratio | 4.45% | 3.53% | 5.78% | 2.97% | 3.55% | -19.70% | 5.32% | 4.77% | 4.17% | 5.85% | 7.07% | 10.69% | 12.73% | 11.85% | 13.79% | 12.23% | 13.74% | 10.07% |
| EPS | 0.15 | 0.12 | 0.21 | 0.11 | 0.15 | -0.80 | 0.19 | 0.15 | 0.14 | 0.13 | 0.05 | 0.06 | 0.05 | 0.05 | 0.07 | 0.05 | 0.05 | 0.03 |
| EPS Diluted | 0.15 | 0.12 | 0.21 | 0.11 | 0.15 | -0.80 | 0.19 | 0.15 | 0.14 | 0.13 | 0.05 | 0.06 | 0.05 | 0.05 | 0.07 | 0.05 | 0.05 | 0.03 |
| Weighted Avg Shares Out | 1.91B | 1.94B | 1.82B | 1.58B | 1.60B | 1.62B | 1.68B | 1.64B | 1.25B | 1.11B | 838.28M | 854.09M | 853.31M | 786.61M | 648.47M | 646.42M | 650.24M | 646.33M |
| Weighted Avg Shares Out (Dil) | 1.91B | 1.94B | 1.82B | 1.58B | 1.60B | 1.62B | 1.68B | 1.64B | 1.25B | 1.11B | 838.28M | 854.09M | 853.31M | 786.61M | 648.47M | 646.42M | 650.24M | 646.33M |
Source: https://incomestatements.info
Category: Stock Reports